Product Images Gemcitabine

Median Progression Free Survival is available for two chemotherapy treatments with Gemcitabine/Carboplatin showing a statistically significant improvement (Log rank p=0.0038) over Carboplatin alone. The median progression-free survival for Gemcitabine/Carboplatin is 8.6 months, while Carboplatin has a median progression-free survival of 5.8 months. The x-axis displays progression-free survival in months and the y-axis shows the number of patients who did not experience progression. The figure contains data for 178 individuals receiving Gemcitabine/Carboplatin and 178 persons receiving Carboplatin alone.*

The text describes the median time (in months) for documented disease progression using two drugs: Gemcitabine/Pacitaxel and Paclitaxel. The results show that Gemcitabine/Pacitaxel has a median time of 5.2 months for documented disease progression, while Paclitaxel has a median time of 2.9 months. The difference is statistically significant with a p-value of less than 0.0001. The data is also shown on a graph that displays the number of patients on each drug over time until disease progression is documented.*

This appears to be a comparison of the survival times (in months) for two different treatments, Gemcitabine/Cisplatin and Cisplatin alone, with N262 patients receiving the latter. The survival times for Gem/Cis and Cis are 9.0 months and 7.6 months, respectively. The statistical analysis showing the Logrank value of 0.008 and Wileoxon value of 0.018 are possibly related to the significance of the difference between the two treatments.*

This appears to be a graph with a title "Fraction Surviving" and a horizontal axis labeled "Survival Time (months)" and a vertical axis labeled "Gemitabine". The graph depicts the percentage of patients surviving over time after treatment with Gemitabine. The numbers along the horizontal axis seem to represent the number of months since initial treatment, while the vertical axis appears to represent the percentage of patients still alive at each point. The data itself is not fully legible, but the graph seems to suggest that survival rates decrease over time.*

Gemcitabine for Injection, USP is a medical product that should only be used for Intravenous purposes and it should be handled with caution as it is cytotoxic. Each vial has 200 mg of the gemcitabine solution and is further diluted before use. The NDC number for this product is 25021-234-10. The other text provided seems to be random characters and does not add any valuable information.*